COMBINATION OF AN INHIBITOR OF HMG-COA-reductase and an inhibitor of farnesyl pyrophosphatase synthase for the treatment of diseases related to the persistence and / or accumulation of prenylated PROTEINS
UNIVERSITÉ D'AIX-MARSEILLE;ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (AFM);ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE;UNIVERSIDAD DE OVIEDO
发明人:
LEVY, NICOLAS,CAU, PIERRE,LOPEZ-OTIN, CARLOS
申请号：
DK07803849
公开号：
DK2034985T3
申请日:
2007.07.05
申请国别(地区):
DK
年份:
2015
代理人:
摘要：
The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.
